Peer Review History

Original SubmissionSeptember 9, 2020
Decision Letter - Quan Jiang, Editor

PONE-D-20-28449

Total Small Vessel Disease Burden and Functional Outcome in Patients with Ischemic Stroke

PLOS ONE

Dear Dr. Ryu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

  1. Question about the reason for not adjusting the multivariate model with the NIHSS score.
  2. English style needs some editing.
  3. Provide more detail information based on reviewer’s suggestions.

Please submit your revised manuscript by Nov 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Quan Jiang, Ph,D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3.Thank you for stating the following financial disclosure:

 [WSR: This work was supported by the Dongguk University Research Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please do the following:

  1. Review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. These amendments should be made in the online form.

  1. Confirm in your cover letter that you agree with the following statement, and we will change the online submission form on your behalf:

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Very interesting paper where the authors use a validated score to evaluate the role of cerebral small vessel disease on stroke outcome.

Major concerns

Could please the authors explain the reason for not adjusting the multivariate model with theNIHSS score?. Has this analysis been performed?. It is a common predictor of functional outcome in patients with stroke and patients with SVD 4 tend to have higher NIHSS scores (p75 is 10).

Minor concerns

Some of the English writing should be reviewed.

The authors use many times in the manuscript the expression “different subtypes of SVD” when they actually refer to different neuroimaging markers of SVD. I suggest use the expressions “SVD markers” or “neurimaging markers of SVD” instead. The “use of subtypes of SVD” can cause confusion to the readers, since SVD has several underlying etiologies such as hypertensive, amyloid angiopathy, CADASIL.. and the expression “SVD subtypes” is frequently used in this setting.

The authors perform a multivariate ordinal regression analysis. Therefore, it would be more correct if they say that “lacunes, MBS… independently increased the risk of worsening on the mRS scale” instead of “lacunes, MBS….were independently associated with unfavorable outcome”, because they analyze the whole spectrum of the scale and not only the unfavorable outcome categories(3-6).

Why have the authors selected the period 2012 to 2013 for the analysis of 90 days mRS?. Don’t they have more recent data?

How many centers participate in the study?. It is not clear from the methods section. At the beginning of this section, the authors say”patients who visited our center”, but lately they say “stroke subtypes were determined by the consensus experienced neurologists in each participating center”.

Reviewer #2: In this study authors evaluated the association between cerebral small vessel disease and functional outcome after ischemic stroke. The study is confirmative, since this observation is not novel in patients with ischemic stroke, but may be of interest because all patients had MR examination and SVD was therefore quantified with the gold standard. Furthermore, the study has been conducted within an Asian cohort of patients whereas many study on the topic were with Caucasian patients, therefore confirms the negative role of SVD on stroke outcome independently of the ethnicity.

The study could be improved and English style needs some editing.

Comments:

- Please report in the abstract number and strength of association rather than p values

- Please present general characteristics of population in the first part of results (age, sex, median NIHSS, etc.)

- Please state inclusion and exclusion criteria for study population. E.g. were included patients treated with acute stroke treatment?

- Please move the excluded patients paragraph from methods to results section

- a single reader rated all the scans

- Table 1 needs some editing (e.g. age, years, probably “mean” is missing). Please add a column with data from all the population.

- What “revascularization” means in the adjusted analysis?

- Although stroke severity (i.e. NIHSS) is a major determinant of stroke outcome, NIHSS is missing in the adjusted analysis. In table 1 there is a clear trend towards worse NIHSS in patients with higher SVD burden. Conversely, in the adjusted analysis

there are some variables that likely do not affect stroke outcome (e.g. smoke exposure, coronary heart disease-anamnestic, I suppose-). I would like to see a further multivariable analysis adjusted simply for age, sex, NIHSS, pre-stroke mRS.

- Figure 1 is rather confusing

- Discussion: there are also reports about no association between SVD and functional outcome after stroke (e.g. Boulouis G et al., Neurology 2019), please discuss your results comparing also with such studies.

- Discussion: as a limit, authors mentioned that patients that were eligible for endovascular treatment were excluded from the study. However, there are reports about SVD and outcomes in such patients (Arba F et al. Neurol Sci 2019; Boulouis G et al., Neurology 2019). Again, what about patients eligible for intravenous rt-PA (see Charidimou A et al., Stroke 2016; IST-3 collaborators, Lancet Neurol; Arba F et al., Acta Neurol Scand 2017)?

- Results apply only to patients who underwent MR, but the great majority of stroke patients receive only CT. Please discuss.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Manuel Gomez-Choco

Reviewer #2: Yes: Francesco Arba

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

We thank the reviewers for taking time. Please refer the attached file "Response to reviewers' comment."

Attachments
Attachment
Submitted filename: Responses to Reviewers Comments.docx
Decision Letter - Quan Jiang, Editor

Total Small Vessel Disease Burden and Functional Outcome in Patients with Ischemic Stroke

PONE-D-20-28449R1

Dear Dr. Ryu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Quan Jiang, Ph,D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: No further comments, all issues have been addressed. The manuscript sounds more complete and limitations are fairly discussed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Manuel Gómez-Choco

Reviewer #2: Yes: Francesco Arba

Formally Accepted
Acceptance Letter - Quan Jiang, Editor

PONE-D-20-28449R1

Total Small Vessel Disease Burden and Functional Outcome in Patients with Ischemic Stroke

Dear Dr. Ryu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Quan Jiang

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .